title: [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
authors.forename: A R J
authors.initials: AR
authors.lastname: Girbes
authors.forename: K H
authors.initials: KH
authors.lastname: Polderman
authors.forename: A
authors.initials: A
authors.lastname: Beishuizen
authors.forename: A R H
authors.initials: AR
authors.lastname: van Zanten
authors.forename: M J
authors.initials: MJ
authors.lastname: Schultz
mesh_terms: D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003257:Consumer Product Safety; D006801:Humans; D017410:Practice Guidelines as Topic; D011486:Protein C / Q000009:adverse effects* / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated